Robert Bota, MD
Psychiatry · Costa Mesa, CANPI 1407990773
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 48 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 23.7% — the pattern of someone who eats at a lot of different presentations.
Across 48 payments — averaging $52.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$594
- Johnson & Johnson$397
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$247
- E.r. Squibb & Sons, L.L.C.$230
- Otsuka America Pharmaceutical, Inc.$146
- Novocure Inc.$133
- plus $763 from 14 others
Across 291 payments — averaging $14,436 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$1.4M
- Teva Pharmaceuticals USA, Inc.$954K
- Hoffmann-la Roche Limited$630K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$485K
- Boehringer Ingelheim$204K
- Merck$147K
- plus $415K from 8 others
What the payments were for
- Food & beverage$2,509100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 7 | $594 |
| Johnson & Johnson | 7 | $397 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $247 |
| E.r. Squibb & Sons, L.L.C. | 3 | $230 |
| Otsuka America Pharmaceutical, Inc. | 2 | $146 |
| Novocure Inc. | 2 | $133 |
| Alkermes, Inc. | 1 | $117 |
| Axsome Therapeutics, Inc. | 1 | $100 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $89 |
| Boehringer Ingelheim | 1 | $82 |
| Corium, LLC | 4 | $73 |
| Noven Therapeutics, LLC | 3 | $62 |
| Sunovion Pharmaceuticals Inc. | 2 | $60 |
| Neuronetics, Inc. | 2 | $51 |
| Lundbeck LLC | 2 | $32 |
| AbbVie | 1 | $23 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| West Therapeutics Development, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$467
- SPRAVATO$268
- CAPLYTA$142
- ABILIFY MAINTENA$120
- ABILIFY ASIMTUFII$120
- LYBALVI$117
- INGREZZA$113
- Auvelity$100
How this compares
$2,509 in reported general payments places this provider in the 85th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DayvigoLemborexant | 13 | $4,306 |
| Tranylcypromine Sulfate | 11 | $893 |
| Bupropion XlBupropion Hcl | 19 | $587 |
| Duloxetine Hcl | 25 | $539 |
| Buspirone Hcl | 15 | $494 |
| Escitalopram Oxalate | 14 | $381 |
| Clonazepam | 25 | $300 |
| Sertraline Hcl | 22 | $229 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 14 | $220 |
| Alprazolam | 25 | $154 |
| Lorazepam | 13 | $100 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Costa Mesa
- Alejandro AlvaCosta Mesa$271K
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.